drugset / Trial / NCT06128148
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
Timeline
- Start
- 2022-05-04
- Primary completion
- 2026-06-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JYP0322 | Unknown | 50 mg | Oral |
| Subject | JYP0322 | Unknown | 100 mg | Oral |
| Subject | JYP0322 | Unknown | 150 mg | Oral |
| Subject | JYP0322 | Unknown | 200 mg | Oral |